Tafamidis attenuates decline of cardiac function in patients with transthyretin amyloid cardiomyopathy: JAMA Niveditha Subramani30 Nov 2023 11:00 AM ISTIn a post hoc analysis of the randomized Tafamidis in Transthyretin Cardiomyopathy Clinical trial, there was less pronounced worsening of left...
ESC 2023 Update: Trial demonstrates potential of acoramidis for transthyretin amyloid cardiomyopathy Dr. Kamal Kant Kohli31 Aug 2023 9:30 AM ISTAcoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo, according to late breaking...
Early tafamidis treatment helps improve survival in patients with transthyretin amyloid cardiomyopathy Dr. Kamal Kant Kohli29 July 2023 10:00 AM ISTUK: In a recent study published in the European Journal of Heart Failure, the researchers have stressed the importance of timely treatment with...
Simple score useful to identify transthyretin amyloid cardiomyopathy in HFpEF patients Medha Baranwal13 April 2023 10:15 AM ISTUSA: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of heart failure with preserved ejection fraction (HFpEF). ATTR-CM can be diagnosed with...
Early cardiac amyloidosis remains serious problem, treat even asymptomatic patients: JACC Dr. Kamal Kant Kohli18 Nov 2022 9:45 AM ISTEarly Cardiac Amyloidosis Still Bad, treat even asymptomatic patients
Tafamidis delays myocardial amyloid progression in transthyretin amyloid cardiomyopathy patients: Study Medha Baranwal9 Dec 2021 9:15 AM ISTAustria: Treatment with tafamidis delays myocardial amyloid progression in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a recent...
